Penalty Amount
$96,500,000
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.
The manufacturers’ settlement funds, totaling approximately $96.5 million, are to be distributed through a claims process to eligible consumers who purchased certain generic drugs. The release does not specify individual consumer award amounts.
This release concerns antitrust settlements, not a privacy enforcement action. In vendor, distribution, and other commercial agreements in the pharmaceutical supply chain, review antitrust compliance representations and covenants, restrictions on sharing competitively sensitive pricing or sales information, and protocols governing communications with competitors. Review employee training and escalation procedures for trade association meetings and other industry contacts; privacy, consent, and breach-notification clauses are not implicated by the facts described here.
Entity
Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure
Industry
Healthcare"Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure"
"totaling approximately $96.5 million"
"claims that those companies illegally conspired to raise the prices of generic drugs."
"This month, the U.S. District Court for the District of Connecticut granted preliminary approval"
"New Jersey and a coalition of 47 other states and territories"
Connecticut and a coalition of 47 other states and territories announced preliminary court approval of a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to inflate drug prices. The release does not give the date of the court’s preliminary approval, so the event date reflects the press release date.
$96.5M
Oregon and a multistate coalition announced a plan to distribute settlement funds to people who paid inflated prices for certain generic drugs. The release says a federal court granted preliminary approval of the distribution plan this month; it does not give the date of that approval, and the reported conduct concerns alleged antitrust violations rather than a privacy violation.
$10.0M
A March 2023 breach at the Perry Johnson companies exposed personal and protected health information belonging to more than 13.3 million people. The companies agreed to pay at least $300,000 in penalties, with an additional $9.7 million payable if they fail to meet the agreement, and to implement security, incident-response, and data-handling reforms.
$220.0M
A 36-attorney-general coalition resolved allegations that General Motors collected and sold identifiable driver behavior and location data to data brokers, which supplied it to insurers for use in assessing drivers and potentially raising premiums. The $220 million nationwide settlement requires affirmative express consent before collecting or disclosing driving and location data, limits data collection, and imposes privacy-program assessments and dealership oversight and training.
New Jersey, the FTC, and a coalition of 19 other states sued Dollar General, alleging that customers were repeatedly charged more at checkout than prices displayed on shelves, tags, and advertisements. The complaint alleges deceptive pricing practices and inadequate safeguards despite consumer complaints; the release does not describe a settlement, penalty, or other remedy imposed.
New Jersey joined a coalition of state attorneys general in filing a notice in Character Technologies, Inc.’s bankruptcy proceedings, raising concerns about the company’s safety and privacy practices and the sensitive conversations it holds, including those involving children and mental health. The states seek safeguards for consumers’ personal information in any sale or transfer of the company’s business or assets; the release does not report a fine or final finding of violations.